<DOC>
	<DOCNO>NCT01838070</DOCNO>
	<brief_summary>This safety surveillance study conduct accordance Korea Food Drug Administration ( KFDA ) `` Basic standard reexamination new drug '' . Primary objective : - To assess safety AVAXIM 160U ( Hepatitis A vaccine ) administer routine practice , accord Korea Food Drug Administration `` Basic standard reexamination new drug '' base pharmaceutical law Korea .</brief_summary>
	<brief_title>Regulatory Post-Marketing Surveillance Study Hepatitis A Vaccine ( AVAXIM 160U )</brief_title>
	<detailed_description>The study conduct real clinical practice accordance Korea Food Drug Administration `` Basic standard reexamination new drug '' . No vaccine provide and/or administer part protocol , however participant receive AVAXIM 160U vaccine administer routine practice accord Summary Product Characteristics part surveillance .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects age 16 year old Informed consent sign subject parent legal representative subject age 16 19 year Informed consent sign subject subject age 20 year age old Receipt AVAXIM 160U accord Summary Product Characteristics ( SmPC ) . Contraindications vaccination accord AVAXIM 160U Summary Product Characteristics ( SmPC ) Subject know pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatitis A</keyword>
	<keyword>Hepatitis A vaccine</keyword>
	<keyword>AVAXIM 160U</keyword>
</DOC>